Artelo Biosciences financials
$4.07−5.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$2.7M | -$2.8M | -$3.1M | -$3.1M | -$2.4M | -$3.8M | -$1.2M | -$2.5M | -$2.6M | -$3.2M | -$2.6M |
| Net income | -$2.4M | -$3.0M | -$4.2M | -$3.1M | -$3.2M | -$2.4M | -$3.8M | -$1.1M | -$2.4M | -$2.5M | -$3.1M | -$2.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-8.01 | $-36.00 | $-38.14 | $-107.19 | $-151.74 | $-112.95 | $-71.01 | $-56.70 | $-122.04 | $-126.36 | $-156.60 | $-134.46 |
| EBITDA | -$2.5M | -$2.7M | -$2.8M | -$3.1M | -$3.1M | -$2.4M | -$3.8M | -$1.2M | -$2.5M | -$2.6M | -$3.2M | -$2.6M |
| Operating cash flow | -$5.0M | -$1.2M | -$2.9M | -$3.5M | -$514.0K | -$1.6M | -$2.6M | -$778.0K | -$2.1M | -$2.9M | -$2.6M | -$1.8M |
| Free cash flow | -$5.0M | -$1.2M | -$2.9M | -$3.7M | -$514.0K | -$1.6M | -$2.6M | -$778.0K | -$2.1M | -$2.9M | -$2.6M | -$1.8M |
| Diluted shares | 0.3M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.2M | $10.3M | $600.0K | $1.7M | $2.1M | $746.0K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $470.0K | $437.0K | $875.0K | $791.0K | $0.00 |
| Total assets | $6.5M | $12.5M | $2.8M | $4.3M | $4.4M | $3.5M |
| Total liabilities | $1.5M | $5.8M | $4.1M | $4.9M | $5.8M | $2.9M |
| Shareholders' equity | $5.0M | $6.7M | -$1.3M | -$633.0K | -$1.4M | $652.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology